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Background and methods: In addition to possess cross drug resistance characteristic, emerging evidences have
shown that multiple-drug resistance (MDR) cancer cells exhibit aberrant metastatic capacity when compared to
parental cells. In this study, we explored the contribution of c-Jun N-terminal kinases (JNK) signaling to the
mesenchymal phenotypes and the aberrant motile capacity of MDR cells utilizing a well characterized MDR cell line
KB/VCR, which is established from KB human epidermoid carcinoma cells by vincristine (VCR), and its parental cell
line KB.
Results: Taking advantage of experimental strategies including pharmacological tool and gene knockdown, we
showed here that interference with JNK signaling pathway by targeting JNK1/2 or c-Jun reversed the mesenchymal
properties of KB/VCR cells to epithelial phenotypes and suppressed the motile capacity of KB/VCR cells, such as
migration and invasion. These observations support a critical role of JNK signaling in maintaining the mesenchymal
properties of KB/VCR cells. Furthermore, we observed that JNK signaling may control the expression of both snail
and twist1 in KB/VCR cells, indicating that both snail and twist1 are involved in controlling the mesenchymal
characteristics of KB/VCR cells by JNK signaling.
Conclusion: JNK signaling is required for maintaining the mesenchymal phenotype of KB/VCR cells; and JNK
signaling may maintain the mesenchymal characteristics of KB/VCR cells potentially through snail and twist1.
Keywords: c-Jun N-terminal kinases, Snail, Twist1, Epithelial mesenchymal transitionBackground
One of major obstacles for successful tumor chemother-
apy is the development of acquired drug resistance, which
possesses a property of cross drug resistance, namely
multiple-drug resistance (MDR). Many efforts have been
made to elucidate the mechanisms of MDR and to de-
velop strategies for overcoming MDR aroused during
chemotherapy [1,2]. On the other hand, studies demon-* Correspondence: ychen@jding.dhs.org; wftan@fudan.edu.cn
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reproduction in any medium, provided the orstrate that cancer cells survived chemotherapy acquire
aberrant metastatic capacity, similar to the phenomena
that cancer cells acquire MDR property after exposed to
chemotherapeutic drugs [3-5]. In this regard, elucidating
the molecular mechanisms underlying aberrant meta-
static capacity of MDR cells is quite important, as it
may provide new targets for improving the efficiency of
chemotherapy.
For metastasis from a primary tumor site, cancer cells
must lose cell-cell adhesion and acquire motility to invade
adjacent cell layers [6]. This process shares many similar-
ities with epithelial-mesenchymal transition (EMT), which
has been proposed as one of critical mechanisms for the
acquisition of metastatic capacity by epithelial cancer
cells [7]. EMT, a highly conserved cellular program intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a biological process through which epithelial cells lose
their epithelial cobblestone phenotype and acquire fi-
broblastic and mesenchymal-like phenotypes. These
dramatic phenotypic changes involve disruption of
intercellular junctions, replacement of apical-basal po-
larity with front to back polarity, and acquisition of
more potent motile ability [8]. The hallmarks of EMT
are characterized by loss of epithelial adhesion mol-
ecule E-cadherin and gain of mesenchymal markers
such as N-cadherin, vimentin, et al. [9]. A wide range
of extracellular signaling pathways have been shown to
trigger the process of EMT, such as signalings elicited
by transforming growth factor-β (TGF-β), fibroblast
growth factor (FGF), epidermal growth factor (EGF),
etc. The stimulation of these signaling pathways results in
the activation of numerous transcriptional factors, inclu-
ding snail1 (hereafter snail), snail2/slug, twist1, ZEB1,
ZEB2, hypoxia inducing factors (HIF), NF-κB, stat3, stat5
and Foxo2, thereby controlling the alterations in gene-
expression patterns that underlie EMT [8,10].
The c-Jun NH2-terminus kinases (JNKs), also called
the stress-activated protein kinase (SAPK), are serine/
threonine kinases that belong to the mitogen-activated
protein kinase (MAPK) family. JNKs are encoded by
three genes, JNK1, JNK2 and JNK3. Two of these genes,
JNK1 and JNK2, are expressed ubiquitously, while JNK3
is selectively expressed in neurons. JNKs can be acti-
vated by environmental stresses, mitogens, and onco-
genes, and play a critical role in tumor development
[11,12]. JNK signaling plays crucial roles in numerous
biological processes such as proliferation, differentiation,
survival and migration through its downstream effector
activating protein1 (AP1), such as c-Jun, JunB, JunD
[11]. Much attention has been focused on the contribu-
tion of JNK signaling in MDR aroused during chemo-
therapy [13,14], whereas the contribution of JNK signaling
to the aberrant motile capacity of MDR cells and its under-
lying mechanisms remain poorly understood. This study
explored the influences of JNK signaling on EMT of MDR
cells to dissect the potential mechanisms underlying the
aberrant motile capacity of MDR cells using a well charac-
terized MDR cell line KB/VCR, a subline established from
a human epidermoid carcinoma cell line KB by vincristine
(VCR), and its parental KB cells [15].
Methods
Materials
Rabbit monoclonal phospho-JNK1/2 and c-Jun were pur-
chased from Cell Signaling Technology (Beverly, MA).
Rabbit monoclonal antiserum against JNK1/2, c-Jun,
E-cadherin, N-cadherin, vimentin, snail, twist1, GAPDH,
and β-actin were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA); SP600125 was purchased from Sigma(St. Louis, MO). JNK1/2 shRNA (50-CCGGAAAGAAT
GTCCTACCTTCTTTCTCGAGAAAGAAGGTAGGACA
TTCTTTTTTTTG-30) and shRNA control cloned into
pMAGIC 7.1 lentiviral system were purchased from Sunbio
(Shanghai, China). The c-Jun siRNA (50-GCGGGAGGC
AUCUUAAUUATT-30) and control were obtained from
GenePharma (Shanghai, China)
Cell lines and transfection
KB human epidermoid carcinoma cells and human epithe-
lial kidney 293 T cells were obtained from the American
Type Culture Collection (Manassas, VA) and maintained
in Dulbecco’s modified Eagle’s medium (Sigma; St. Louis,
MO) containing 10% fetal calf serum. The VCR-selected
multiple-drug tolerant KB/VCR subline was obtained from
Zhongshan University of Medical Sciences (Guangzhou,
China) and routinely cultured in medium containing VCR
(200 ng/ml). KB/VCR cells were cultured in VCR-free
medium for at least 3–7 days prior to be used for experi-
ments to avoid drug-associated secondary effects, and were
cultured in absence of VCR for no more than 15 days to
keep the MDR phenotype. The KB/VCR resistant cells
were authenticated by comparing their fold resistance with
that of the parental cells and examining the expression
level of ABC transporters (ABCB1 and ABCG2) in KB/
VCR cells cultured in the presence, or absence of VCR for
about 15 days.
The c-Jun siRNA and control were transfected to
KB/VCR cells using lipefectamine 2000 (Invitrogen;
Carlsbad, CA) as the instructions provided by the
manufacturer.
shRNA and lentivirus infections
The JNK1/2 shRNA and control were transfected to
293 T cells using lipefectamine 2000 (Invitrogen; Carlsbad,
CA) as the instructions provided by the manufacturer.
Viral stocks were prepared and infections performed as
previously reported [16].
Migration and invasion assay
Migration assay and invasion assay were determined using
a transwell system (Corning Costar; Acton, MA) with an 8-
μm pore size membrane coated with fibronectin for migra-
tion assay or with matrigel for invasion assay as described
by Li et al. [17]. Briefly, 100 μl (5 × 104 cells) of KB or KB/
VCR cells was added to the upper wells and 600 μl of
DMEM with or without 10% FBS, which was used as a che-
moattractant, was added to the lower wells. After incuba-
tion for 8 h at 37°C, the migrated cells or invaded cells
were fixed with 90% EtOH and then stained with 0.1% crys-
tal violet in 0.1 mol/L borate and 2% EtOH (pH 9.0). The
stained cells were subsequently extracted with 10% acetic
acid. The absorbance values were determined at 570 nm
with a Spectrophotometer (BioTek; Winooski, VT).
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Total RNA was isolated with the RNAiso Plus Kit from
TaKaRa (Dalian, China) as the instructions provided by
the manufacturer. Total RNA was reversely transcribed
using Moloney Murine Leukemia Virus (M-MLV) re-
verse transcriptase (TaKaRa; Dalian, China) and cDNAs were
used for PCR with the following primers (Invitrogen; Shang-

















CAAATCGCTTGG-30. The PCR products were ana-
lyzed using agarose gel electrophoresis.
Real time-PCR analyses
Total RNA was subjected to reverse transcription with the
kit from TaKaRa (Dalian, China) according to the manu-
facturer’s instructions. Then the cDNAs were amplified by
Real-time PCR (iQ5; Bio-Rad) with the SYBR-Green kit
(TaKaRa, Dalian, China) with the primers (Invitrogene;
Shanghai, China) mentioned above. The alteration of
mRNA expression in cells was assessed using the iQ5 op-
tical system software by delta delta Ct method.
Immunoblot analysis
Cells were lysed in lysis buffer (50 mM Tris–HCl,
150 mM NaCl, 1% Nonidet P-40) supplemented with
protease inhibitors (0.5 mM phenylmethylsulfonyl fluor-
ide, 1 μg/ml aprotinin and leupeptin) for 15 min on ice.
Equal amounts of protein were subjected to SDS-
polyacrylamide gel electrophoresis and transferred onto
a polyvinylidene difluoride membrane (Immobilon P;
Millipore). The membranes were then incubated with
the appropriate antibodies as indicated.
Statistical analysis
The data of the experimental studies were expressed as
the average ± s.d. Statistical differences were analyzed by
the two-tailed Student’s t test and P < 0.05 was consid-
ered as significant.Results
KB/VCR cells exhibit mesenchymal properties and aberrant
motile capacity compared to the parental cells KB
We employed the MDR cell line KB/VCR, a well
established MDR cell line [15], to firstly explore whether
the MDR cells possess mesenchymal properties. We ob-
served that the KB/VCR cells exhibited elongated, fibro-
blastic morphology (Figure 1A). On the contrary, the
parental cells KB exhibited epithelial cobblestone pheno-
type (Figure 1A). These observations suggested that the
KB/VCR cells lost the epithelial morphology and ac-
quired mesenchymal phenotype when compared to pa-
rental KB cells. We next evaluated the expression of
markers for epithelial and mesenchymal characteristics
in KB/VCR cells and parental KB cells with western blot
analysis. In line with the alterations in morphology be-
tween KB/VCR and KB cells, we found that the expres-
sion of the epithelial marker E-cardherin was decreased
in KB/VCR cells compared to KB cells, while the expres-
sion of mesenchymal markers including N-cadherin and
vimentin was increased when compared to KB cells
(Figure 1B). We then sought to compare the motile
behavior including migration and invasion abilities be-
tween KB cells and KB/VCR cells utilizing a transwell
system. Our results revealed that KB/VCR cells mi-
grated and invaded more efficiently than KB cells in
response to 10% serum, which was used as a chemo-
attractant (Figure 1C-D). These data together indicate
that KB/VCR cells undergo epithelial-mesenchymal
transition and acquire more powerful motile capacity
in comparison to KB cells.
Pharmacological inhibition of JNK1/2 activation with
SP600125 reverses the mesenchymal phenotypes of KB/
VCR cells
JNK signaling has been implicated in the occurrence of
MDR during chemotherapy [13,14], whereas there is lit-
tle knowledge regarding the contribution of JNK signal-
ing to EMT properties and motile ability of MDR cells.
We then set out to explore the influence of JNK signal-
ing on the mesenchymal phenotypes of MDR cells. To
this end, we firstly assessed whether JNK signaling is ac-
tivated in KB/VCR cells by evaluating the phosphoryl-
ation status of JNK1/2 and c-Jun, a key transcription
factor downstream of JNK1/2. Western blot analysis re-
vealed that JNK1/2 and c-Jun were obviously phosphory-
lated when compared to that in KB cells, whereas there
was no alteration in the total protein expression for
JNK1/2 and c-Jun. These results suggest that JNK signal-
ing is activated in KB/VCR cells when compared to KB
cells (Figure 2A). Keeping this in mind, we then asked
whether interference with JNK signaling would disrupt
the mesenchymal properties of KB/VCR cells. We began













































































Figure 1 KB/VCR cells exhibit mesenchymal properties compared to parental KB cells. A. KB/VCR cells exhibit elongated, fibroblastic
morphological alterations, whereas the KB cells displayed epithelial cobblestone phenotype. (×10). B. Expression of epithelial markers E-cadherin
in KB/VCR cells is decreased, concomitantly with increased expression of mesenchymal markers N-cadherin and vimentin, when compared to KB
cells. KB and KB/VCR cells were lysed and used for western blotting analysis, using the GAPDH as a loading control. All blots present in this paper
are representatives from at least three independent experiments. Values quantified by Image J from three independent experiments were
statistical different. C-D. KB/VCR cells possess more potent motile behavior ability, including migration (C: *P < 0.05 compared to KB negative
control; ** P < 0.05 compared to KB with 10%FBS) and invasion (D: *P < 0.05 compared to KB negative control; ** P < 0.01 compared to KB with
10%FBS) in response to serum, in comparison to KB cells. KB/VCR cells or KB cells were loaded into the upper wells, while the growth medium
containing 10% serum was added into the lower wells of transwell system with a membrane coated by fibronectin or matrigel, and Serum free
medium was used as a negative control. After 8 h, the migrated or invaded cells onto membranes were fixed and quantified as described in
materials and methods. Values are the average ± SD of results obtained from three separated experiments.
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SP600125 (SP), a specific and widely used antagonist of
JNKs [18], to inhibit the JNK1/2 activity in KB/VCR
cells. As expected, treatment of KB/VCR cells with SP
significantly suppressed the phosphorylation of JNK1/2
and c-Jun in KB/VCR cells (Figure 2B), confirming that
SP can be useful for investigating the contribution of
JNK1/2 in maintaining the mesenchymal phenotype of
KB/VCR cells. After treated with SP 10 μM for 24 h, the
KB/VCR cells lost the fibroblatic mesenchymal morph-
ology and recovered the epithelial cobblestone pheno-
type (Figure 2C) similar to that possessed by KB cells as
shown in Figure 1A. Meanwhile, exposure of the KB/
VCR cells with SP 10 μM for 24 h obviously reduced the
expression of mesenchymal markers N-cadherin and
vimentin in KB/VCR cells, accompanying with elevated
expression of epithelial marker E-cadherin (Figure 2D).
Moreover, we observed that the expression of epithelial
and mesenchymal markers in KB/VCR cells after treated
with SP was almost recovered to that in KB cells
(Figure 2D). In line with these alterations in the expres-
sion of epithelial and mesenchymal markers, we found
that after treatment with SP, the migration (Figure 2E)and invasion (Figure 2F) of KB/VCR cells in response to
serum were abundantly suppressed. Taken together,
these observations support that JNK1/2 activation is re-
quired for maintaining the mesenchymal properties of
KB/VCR cells.
Knockdown of JNK1/2 reverses the mesenchymal
phenotype of KB/VCR cells
To further address the direct role of JNK1/2 activation
in maintaining the mesenchymal characteristics of KB/
VCR cells, we set out to knockdown JNK1/2 using RNA
interference approach. We designed a shRNA sequence
targeting both JNK1 and JNK2 and expressed it stably in
KB/VCR cells using a lentiviral system. The western blot
analysis revealed that the expression of JNK1/2 in KB/
VCR cells infected with lentiviral mediated JNK1/2
shRNA was significantly decreased when compared to
that of cells infected with the shRNA control (Figure 3A).
Consequently, we observed that the phosphorylation of
c-Jun was also reduced as anticipated (Figure 3A).
Meanwhile, we found that limiting expression of JNK1/2
resulted in KB/VCR cells re-gaining an epithelial cobble-
stone phenotype (Figure 3B), which was similar to that of
C
































































































Figure 2 Pharmacological inhibition of JNK1/2 activation with SP reverses the mesenchymal phenotypes of KB/VCR cells. A. KB/VCR
cells display enhancement level of p-JNK1/2 and p-c-Jun when compared to KB cells. The expression of p-JNK1/2, p-c-Jun and their total proteins
was analyzed by Western blot with specific antibodies, using antibody to β-actin as a loading control. B. Suppression of JNK signaling by SP
inhibits the phosphorylation of JNK1/2 and c-Jun in KB/VCR cells. KB/VCR cells were treated with SP (10 μM) for 24 h, and the proteins were then
harvested for western blot analysis as mentioned in materials and methods. C. Exposure of KB/VCR cells to SP 10 μM for 24 h renders the KB/VCR
cells losing the mesenchymal fibroblastic morphology and recovering epithelial cobblestone phenotype. (×10). D. Treatment of KB/VCR cells with
SP recovers the expression pattern of epithelial and mesenchymal markers in KB/VCR cells similar to those in KB cells. KB/VCR cells treated with SP
(10 μM) for 24 h were lysed and used for western blot analysis of EMT protein markers. Proteins extracted from KB cells were used as a control.
E-F. Interfering with JNK1/2 by use of SP inhibited the migration (E: *P < 0.05 compared to KB; **P < 0.05 compared to control) and invasion
(F: *P < 0.05 compared to KB; **P < 0.001 compared to control) of KB/VCR cells in response to serum. Cells were loaded into upper well, while the
SP (10 μM) was added together with medium containing 10% FBS to the lower wells. Data are expressed as average ± SD of results obtained
from three separated experiments. In all cases, blots are representative of three to four independent experiments.
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blastic morphology of KB/VCR cells infected with shRNA
control (Figure 3B). In alignment with the results obtained
by the pharmacological tool SP, limiting the expression of
JNK1/2 led to increase the expression of epithelial marker
E-cadherin and to decrease the expression of mesenchymal
markers N-cadherin, vimentin, when compared to that of
the KB/VCR cells infected with shRNA control (Figure 3C).
Furthermore, we observed that knockdown the expression
of JNK1/2 obviously inhibited the migration and invasion
of KB/VCR cells responding to serum (Figure 3D, E). These
observations together with those obtained by small molecu-
lar antagonist SP demonstrate that JNK1/2 activation isquite important for maintaining the mesenchymal pheno-
type of KB/VCR cells.
Knockdown of c-Jun disrupts the mesenchymal
phenotype of KB/VCR cells
The oncogenic function of JNKs is mostly based on their
ability to phosphorylate c-Jun [11]. We then further investi-
gated the efficiency of c-Jun on the mesenchymal pheno-
type of KB/VCR cells by eliminating the expression of c-
Jun with small RNA interference approach. As expected,
limiting the expression of c-Jun (Figure 4A) caused eleva-
tion of the expressions of epithelial marker E-cadherin and









































































































Figure 3 Knockdown of JNK1/2 reverses the mesenchymal phenotypes of KB/VCR cells. A. Knockdown of JNK1/2 by lentiviruses carrying JNK1/2
shRNA. KB/VCR infected with lentiviruses carrying shRNA control or JNK1/2 shRNA were lysed after infection, and used for Western blot analysis. Western blot
for GAPDH was used as a loading control. Data are similar results from three independent experiments. B. Knockdown the expression of JNK1/2 by JNK1/2
shRNA results in KB/VCR cells acquiring of epithelial cobblestone like morphology contrast to that of shRNA control. (×10). C. Knockdown of the expression of
JNK1/2 significantly increases the expression of E-cadherin and obviously decreases the expression of N-cadherin, vimentin in KB/VCR cells. The expression of
E-cadherin, N-cadherin and vimentin was examined as described above in KB/VCR cells after infection with lentiviruses carrying shRNA control or JNK1/2
shRNA. Data are representative blots from three independent experiments. D-E. Knockdown of the expression of JNK1/2 significantly inhibits the migration
(C: *P < 0.001 compared to KB; **P < 0.01 compared to control shRNA) and invasion (D: *P < 0.05 compared to KB; **P < 0.05 compared to control shRNA) of
KB/VCR cells in response to serum. The migration and invasion of KB/VCR cells in response to serum were examined as described above after infection with
lentiviruses carrying shRNA control or JNK1/2 shRNA. Data are expressed as average ± SD of results obtained from three separated experiments.
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(Figure 4A), paralleling to the observations achieved via
interference with JNK1/2 by pharmacological and shRNA
approaches. Consistent with the changes in the expression
of epithelial and mesenchymal markers, knocking down
the expression of c-Jun also resulted in preventing the mi-
gration and invasion of KB/VCR cells in response to serum
(Figure 4B, C). These data together indicate that c-Jun, as
well as JNK1/2, may be involved in maintaining the mesen-
chymal phenotype of KB/VCR cells, further supporting the
argument that the JNK signaling is strictly required for
maintaining the mesenchymal properties of KB/VCR cells.
Snail and twist1 are both involved in maintaining the
mesenchymal properties of KB/VCR cells by JNK signaling
A wide range of transcriptional factors activated by
extracellular signaling have been directly or indirectlyimplicated in controlling the expression of epithelial and
mesenchymal markers and eventually the phenotypes of
EMT [10]. We thus sought to explore the potential tran-
scriptional factors involved in the mesenchymal pheno-
types maintained by JNK signaling in KB/VCR cells.
Using RT-PCR approach, we firstly detected the expres-
sion of a panel of transcriptional factors including snail,
slug, twist1, HIF1α, NF-κB, Foxo2, ZEB1, ZEB2, stat3
and stat5a, which all have been well characterized in in-
ducing of EMT [10], at transcript level in KB/VCR cells
compared to parental ones. Of interest, we observed that
there were no alterations in the expression at transcript
levels of the majority of those transcriptional factors,
with exemption of snail and twist1, whose expression at
mRNA level was obviously elevated in KB/VCR cells
compared to that of parental KB cells (Figure 5A). This
observation was further validated by real time PCR and
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Figure 4 Knockdown of c-Jun disrupts the mesenchymal phenotypes of KB/VCR cells. A. Expression of c-Jun, E-cadherin, N-cadherin and
vimentin after knockdown of c-Jun with RNA interfering approach. KB/VCR cells transfection of siRNA targeting c-Jun or siRNA control were lysed
and used for western blot analysis with specific antibodies. Blots are representative of three independent experiments. B-C. Limiting the
expression of c-Jun with siRNA reduces the migration (B: * P < 0.01) and invasion (C: *P < 0.05) of KB/VCR cells. The migration and invasion of KB/
VCR cells in response to serum were examined as described above after transfection with c-Jun siRNA and the siRNA control. Data are expressed
as average ± SD of results obtained from three separated experiments.
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spectively (Figure 5B-C), thus suggesting the possibility of
those two transcriptional factors being involved in mediat-
ing the EMT controlled by JNK signaling in KB/VCR cells.
We then set out to gain direct evidences regarding the in-
volvement of snail and twist1 in the mesenchymal proper-
ties controlled by JNK signaling in KB/VCR cells.
Blockade of JNK1/2 activation with pharmacological tool
SP (Figure 5D) or JNK1/2 shRNA (Figure 5E) approaches
caused an obviously reduction in the expression of snail
and twist1 when compared to that of control KB/VCR
cells. Similar results were observed by mean of silencing
the expression of c-Jun with siRNA (Figure 5F). Collect-
ively, these observations suggest that JNK signaling may
control the mesenchymal properties of KB/VCR cells
through acting on both snail and twist1.Discussion
In the present study, we utilized MDR cells KB/VCR
[15], a well established MDR cell line possessing high re-
sistance index and its parental one to examine the po-
tential contribution of JNK signaling to EMT and
aberrant motile capacity of MDR cells. By combinations
of morphological, biological markers and functional ana-
lysis, we observed that KB/VCR cells possess mesenchy-
mal properties with more potent motile capacity in
comparison to KB cells, indicating that KB cells under-
went EMT at the process of acquiring MDR. Further-
more, taking advantage of pharmacological tool and
gene knockdown approaches, we demonstrated that JNKsignaling may strictly be required for maintaining the
mesenchymal properties of KB/VCR cells and its aber-
rant motile capacity through acting on snail and twist1,
two critical transcriptional factors for EMT [10].
EMT, initially identified by its critical roles in develop-
mental program of embryogenesis, has been demonstrated
to be critical for numerous aspects of tumor progression,
including proliferation and survival of tumor cells [19].
Moreover, transition of epithelial cancer cells to mesenchy-
mal ones results in alterations in adhesive properties, acti-
vation of proteolysis and enhancement of motility, thereby
endowing cancer cells the ability to invade and disseminate
from primary location to distal organs sites and finally pro-
moting metastasis of cancer [7,19]. Prior studies have
shown that MDR cells acquire EMT transition compared
to parental ones [20-22]. Aligned with these prior studies,
our observations derived from KB/VCR and KB cells fur-
ther validated this argument that cancer cells undergo
EMT at the process of acquiring MDR. Thus, our data to-
gether with prior studies support that acquired mesenchy-
mal properties may contribute, at least partially, to the
aberrant motile and metastasis capacity of MDR cells arose
during the process of chemotherapy.
JNK signaling has been implicated in numerous as-
pects of cancer progression, including the initiation, pro-
liferation, survival and metastasis of cancers [11,23-26],
as well as the occurrence of MDR during chemotherapy
[11]. Emerging evidences have proven that JNK signaling
promotes the metastasis of cancers, most likely through
acting on matrix metalloproteinases [27-29], or on the

























































































Figure 5 Snail and twist1 are both involved in maintaining the mesenchymal properties of KB/VCR cells controlled by JNK signaling. A.
RT-PCR analysis for the expression of transcriptional factors associated with EMT in KB and KB/VCR cells. Total RNA of KB and KB/VCR cells was
extracted and reversed to cDNA, which was subsequently subjected to PCR analysis with specific primers as indicated in materials and methods.
B. Expression of snail and twist1 at mRNA level was determined by real time PCR analysis (*P < 0.01; **P < 0.05). C. Expression of snail and twist1
at protein level was determined by western blot analysis. D-E. Interfering with JNK1/2 with SP (D) or JNK1/2 shRNA (E) suppressed the expression
of snail and twist1 in KB/VCR cells. KB cells or KB/VCR cells treated with SP 10 μM after 24 h or after infected with JNK1/2 shRNA were lysed and
subjected to western blot analysis using specific antibodies. Western blot for β-actin was used as a loading control. F. Knockdown of c-Jun with
siRNA reduces the expression of snail and twist1 in KB/VCR cells. KB cells or KB/VCR cells transfected with c-Jun siRNA or control were lysed, and
used for western blot analysis with specific antibodies. In all cases, blots are representative of three to four separate experiments.
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sion protein of JNK and its upstream activator MKK7,
Wang et al. recently reported that JNK activation can
promote EMT in breast cancer cells [31]. In the current
work, we observed that inhibition of JNK function via
SP or knockdown of JNK expression may reverse the
mesenchymal phenotypes of MDR cells KB/VCR. In
addition, we further demonstrated that knockdown of c-
Jun, a critical downstream transcriptional factor of JNK
signaling, may disrupt the mesenchymal properties of
KB/VCR cells as well. Many signaling pathways have
been shown to be activated and play critical roles in
maintaining the acquired chemoresistance, such asNotch and Hedgehog signaling pathways [32,33]. Hence,
it is not surprising that Notch and Hedgehog signaling
may be responsible for the activation of JNK signaling in
KB/VCR acquired chemoresistant cancer cells. Indeed,
we observed that JNK signaling was activated by the
Hedgehog in acquired chemoresistant cancer cells via a
cell autonomous manner, resulting in acquisition of
EMT phenotype as presented in this study and activa-
tion of the Gli transcriptional factor of Hedgehog path-
way (unpublished data from our lab). In turn, Gli
activation may also increase the abundances of ABCB1
and ABCG2 [33,34]. Taken together, our data provide
evidences that JNK signaling is strictly required for
Zhan et al. BMC Cancer 2013, 13:180 Page 9 of 10
http://www.biomedcentral.com/1471-2407/13/180maintaining the mesenchymal properties of MDR cells,
thus possibly involved in the aberrant metastasis cap-
acity of MDR cells.
A variety of transcription factors including snail, slug,
twist1, Zeb1 and Zeb2, to name a few, are involved in
the EMT, through directly or indirectly regulating the
expression of epithelial and mesenchymal markers, such
as E-cadherin, N-cadherin etc. [19]. In this study, we ob-
served that both snail and twist1 were elevated in the
MDR cells KB/VCR in comparison to its parental KB
cells, indicating the involvement of both snail and twist1
in the acquisition of mesenchymal phenotypes of MDR
cells. This is discrepant to the finding from others that
twist1 is solely involved in the EMT of drug resistant
breast cancer cells acutely selected by lethal dose of
adriamycin [20]. This discrepancy may be likely due to
distinct systems used in these studies. We further found
that the expression of snail and twist1 are both con-
trolled by the JNK signaling, thus providing evidence
that JNK signaling likely controls the mesenchymal phe-
notypes of MDR cells through acting on both snail and
twist1. Our observations provide original interpretation
of the molecular mechanisms for JNK signaling in regu-
lation of EMT and in promotion of cancer metastasis.
Although great progresses have been made in the devel-
opment and clinical usage of molecular target anti-cancer
drugs, chemotherapy using conventional cytotoxic anti-
cancer drugs is still one of efficient approaches for treat-
ment of cancers, in despite of its limitations including
MDR. Accumulating evidences have also shown that che-
motherapeutic drugs usage can cause a secondary metas-
tasis of survival cancer cells during chemotherapy and
that MDR cancer cells possess aberrant metastatic cap-
acity when compared to those sensitive to chemothera-
peutic drugs [3-5]. In this regard, it is not surprising that
the acquired more potent metastatic ability of MDR cells
caused by traditional cytotoxic drugs usage may heavily
hamper the chemotherapeutic efficacy, like MDR does.
Furthermore, in addition to be involved in cancer metasta-
sis, increasing evidences demonstrate that EMT program
may also contribute to the occurrence of MDR through
regulating the properties of cancer stem cell, which is sig-
nificantly resistant to chemotherapy drugs [35-37].
MAPKs, such as ERK, JNK, and p38MAPK, are activated
in multiple drug resistance cells [38]. However, the role of
JNK activation in acquired chemoresistance still remains
controversial [39]. Hence, this study may provide indica-
tions for interpreting the contributions of JNK signaling
to MDR, through controlling the mesenchymal properties
of MDR cells via acting on snail and twist1. Indeed, we ob-
served that interfering with the expression of snail or
twist1, which were both controlled by the JNK signaling
as observed in this study, led to circumvent the MDR of
KB/VCR cells (data to be published).Conclusions
In conclusion, the finding that JNK signaling may con-
trol mesenchymal properties of MDR cells KB/VCR via
snail and twist1 implicates a potential therapeutic target
for improving limitations and efficacy of chemotherapy,
ranging from reversal of MDR to prevention of secondly
metastasis caused by chemotherapeutic drugs usage.
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